Overview

Study of SPG302 in Adults With Schizophrenia

Status:
RECRUITING

Trial end date:
2026-02-01

Target enrollment:

Participant gender:

Summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Phase:

PHASE2

Details

Lead Sponsor:

Spinogenix